Abstract:Cancer drug testing in animals is an extremely poor predictor of the drug's safety and efficacy observed in humans. Hence there is a pressing need for functional testing platforms that better predict traditional and immunotherapy responses in human, live tumor tissue or tissue constructs, and at the same time are compatible with the use of mouse tumor tissue to facilitate building more accurate disease models. Since many cancer drug actions rely on mechanisms that depend on the tumor microenvironment (TME), such platforms should also retain as much of the native TME as possible. Additionally, platforms based on miniaturization technologies are desirable to reduce animal use and sensitivity to human tissue scarcity. Present high-throughput testing platforms that have some of these features, e.g. based on patient-derived tumor organoids, require a growth step that alters the TME. On the other hand, microdissected tumors (μDTs) or "spheroids" that retain an intact TME have shown promising responses to immunomodulators acting on native immune cells. However, difficult tissue handling after microdissection has reduced the throughput of drug testing on μDTs, thereby constraining the inherent advantages of producing numerous TME-preserving units of tissue for drug testing. Here we demonstrate a microfluidic 96-well platform designed for drug treatment of hundreds of similarly-sized, cuboidal μDTs ("cuboids") produced from a single tumor sample. The platform organizes a monodisperse array of four cuboids per well in 384 hydrodynamic traps. The microfluidic device, entirely fabricated in thermoplastics, features 96 microvalves that fluidically isolate each well after the cuboid loading step for straightforward multi-drug testing. Since our platform makes the most of scarce tumor tissue, it can potentially be applied to human biopsies that preserve the human TME while minimizing animal testing.

A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity

Application of a Microfluidic Chip-Based 3D Co-Culture to Test Drug Sensitivity for Individualized Treatment of Lung Cancer.

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

An Oxygen-Concentration-Controllable Multiorgan Microfluidic Platform for Studying Hypoxia-Induced Lung Cancer-Liver Metastasis and Screening Drugs

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

Scientific Validation and Clinical Application of Lung Cancer Organoids

Rapid anticancer drug screening using patient-derived lung cancer organoids: a case report

Microfluidic Organoids-on-a-Chip: Quantum Leap in Cancer Research

Microfluidic Platform for Generating and Releasing Patient‐Derived Cancer Organoids with Diverse Shapes: Insight into Shape‐Dependent Tumor Growth

A versatile dilution-treatment-detection microfluidic chip platform for rapid In vitro lung cancer drug combination sensitivity evaluation

Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week

A Tumor‐Organoid‐Based Precision Medicine Platform for the Prediction of Drug Sensitivity of Colorectal Cancer

Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening

Patient-derived organoids of lung cancer based on organoids-on-a-chip: enhancing clinical and translational applications

Moving toward precision medicine with lung cancer organoids

A dual-functional microfluidic chip for guiding personalized lung cancer medicine: combining EGFR mutation detection and organoid-based drug response test

In vitro construction of lung cancer organoids by 3D bioprinting for drug evaluation

Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review

Drug testing of monodisperse arrays of live microdissected tumors using a valved multiwell microfluidic platform

Progress and application of lung-on-a-chip for lung cancer

Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy